

Accurate quantification of modified cyclic peptides without the need for authentic standards  
Rosemary I. Adaba a, Greg Mann b, Andrea Raab c, Wael E. Houssen a, d, e, Andrew R. McEwan a, d, Louise Thomas a, d, Jioji Tabudravu a, James H. Naismith b, Marcel Jaspars a

- . a Marine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Meston Walk, Aberdeen, AB24 3UE, UK
- . b Biomedical Sciences Research Complex, University of St Andrews, North Haugh, St Andrews, Fife, KY16 9ST, UK
- . c TESLA, Department of Chemistry, University of Aberdeen, UK
- . d Institute of Medical Sciences, University of Aberdeen, Aberdeen, AB25 2ZD, UK
- . e Pharmacognosy Department, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt

## Abstract

There is a growing interest in the use of cyclic peptides as therapeutics, but their efficient production is often the bottleneck in taking them forward in the development pipeline. We have recently developed a method to synthesise azole-containing cyclic peptides using enzymes derived from different cyanobactin biosynthetic pathways. Accurate quantification is crucial for calculation of the reaction yield and for the downstream biological testing of the products. In this study, we demonstrate the development and validation of two methods to accurately quantify these compounds in the reaction mixture and after purification. The first method involves the use of a HPLC coupled in parallel to an ESMS and an ICP-MS, hence correlating the calculated sulfur content to the amount of cyclic peptide. The second method is an NMR ERETIC method for quantifying the solution concentration of cyclic peptides. These methods make the quantification of new compounds much easier as there is no need for the use of authentic standards when they are not available.

## 1. Introduction

The growing application of peptides in drug discovery necessitates their accurate quantification in order to obtain the right metabolic, enzymatic, kinetic and pharmacokinetic data.<sup>1–6</sup> Several methods for peptide quantification have been reported to date, these include liquid chromatography combined with ultraviolet (UV) or fluorescence detection, capillary electrophoresis with UV detection, matrix-assisted laser-desorption/ionization mass spectrometry (MALDI-MS), surface-enhanced laser desorption/ionization (SELDI),<sup>6–12</sup> liquid chromatography-mass spectrometry (LC-MS),<sup>7,8</sup> inductively coupled plasma mass spectrometry (ICP-MS)<sup>13,14</sup> and quantitative nuclear magnetic resonance (qNMR).<sup>9</sup>

Limitations of these techniques for quantification of peptides vary by technique. Matrix effects limit optical techniques such as UV and fluorescence detection.<sup>7,8</sup> Different mass spectrometric methods suffer from different problems. Matrix-assisted laser desorption/ionization–time of flight mass spectrometry (MALDI-TOF) and electrospray ionization (ESMS) techniques both suffer drawbacks such as differential response of proteins and peptides depending on size, hydrophobicity, matrix, or solvents.<sup>10</sup> At low mass resolution, LC-MS data has a limited accuracy for reported intensity of the extracted ion currents due to contamination by nearby peptide signals, thereby affecting accurate quantification.<sup>11,12</sup> For quantification purposes, it is necessary to address these issues in particular ionization efficiency and matrix effects when using an ESMS or MALDI-MS direct measurements. For this reason various sample treatments for MS-based quantification are reported in the literature for peptides including; isotope-coded affinity tag reagents (ICATs),<sup>13–15</sup> isotope-coded protein labelling (ICPL),<sup>16–18</sup> stable isotope labelling by amino acid in cell culture (SILAC),<sup>19–21</sup> isotope-differentiated binding energy shift tag (IDBEST), chemical labelling, isobaric tagging (iTRAQ, TMT),<sup>22,23</sup> and absolute quantification with the use of synthetic labelled peptides (AQUA),<sup>24,25</sup> These methods require additional sample preparation and cost.

ICP-MS is a sensitive analytical tool for elemental analysis with advantages of having species independence and high ionization efficiency for most elements in the periodic table, high sensitivity of parts per billion to parts per trillion levels, together with affordable isotope distribution information.<sup>26,27</sup> For these reasons it has become a significant and complementary technique in bioanalysis for the determination of biomolecules and quantification of therapeutic agents.<sup>28–36</sup> Application of ICP-MS allows the quantification of elements independent of their molecular form, hence the analyte retains its original form during quantification. Coupled with molecular information obtained from ESMS or MALDI enables the compound identification simultaneously with its quantification. Sulfur has been successfully used for the quantification of proteins and peptide in biological samples by coupling the ICP-MS to different chromatographic systems.<sup>37–40</sup>

NMR produces a signal for any species that will have an area that is proportional to its concentration.<sup>40</sup> Complex mixtures can be analysed by NMR which provides the concentration of the chemical components in a mixture, hence allowing quantification of species for metabolomic and related studies.<sup>41,42</sup> Proton NMR quantification (qNMR) by ERETIC is a non-destructive and rapid way of providing accurate analyte concentrations<sup>43</sup> by using an indirect internal reference signal that represents a known concentration. This averts the need to determine a compound-specific response factor,<sup>44</sup> making qNMR an accurate and straightforward technique for quantification. The drawbacks to this method are that it requires relatively pure samples of large size that would allow sufficient signal to noise ratio (>150:1)<sup>9</sup> and an internal certified reference material.

Cyclic peptides show promise in many therapeutic areas, particularly in complex diseases such as auto-immune disorders.<sup>45</sup> Cyanobactins are a family of modified cyclic peptides that have interesting structural features including heterocycles, epimerized stereocentres and prenylated residues (Fig. 1).<sup>46</sup> Some of these modifications lead to better target affinity by constraining

conformational flexibility, while others increase cellular permeability.<sup>47,48</sup> Members of cyanobactins are known to reverse multi drug resistance in human lymphoblasts by inhibiting the P-glycoprotein (Pgp) drug efflux pump.<sup>49–51</sup>

Patellamides are the most studied members of the cyanobactins. They were originally isolated from extracts of the Indo-Pacific ascidian *Lissoclinum patella*, but shown later to be produced by its cyanobacterial symbiont *Prochloron* sp.<sup>52,53</sup> Genomic studies of *Prochloron* sp. delineated the gene cluster for the biosynthesis that directs the production of the patellamides.<sup>54–59</sup> Their biosynthesis occurs via the production of a ribosomally encoded precursor peptide, in which a core peptide sequence is modified by a series of processing enzymes.<sup>52,60–64</sup> We recently used these enzymes *in vitro* to generate natural and non-natural cyanobactins in milligram quantities.<sup>61</sup> Accurate quantification of the reaction products is essential to calculate yields before and after purification and for their downstream biological screening but is challenging due to the lack of authentic standards.

To overcome this, we herein report two quantification methods, the first relies on the quantification of the sulfur content in the products to estimate the concentration of these new heterocycle containing cyclic peptides in solutions, by coupling molecular electrospray mass spectrometry (ESMS) and elemental inductively coupled plasma mass spectrometry (ICP-MS) to a high pressure liquid chromatograph (HPLC) in parallel.<sup>65</sup> Using this approach we quantified sulfur containing peptides obtained after extraction and purification of these compounds from chemoenzymatic reaction mixtures and identified the most efficient extraction and purification strategy. While the second method describes an alternative quantification method using NMR and an ERETIC (electronic reference to access *in vivo* concentrations) reference for the quantification of non-sulfur containing cyclic peptides. ERETIC qNMR enabled us to obtain the concentration and identity of these new compounds simultaneously.

## 2. Results and discussion 2.1. Verification of sulfur quantification by HPLC

Two sulfur containing compounds **1** and **2** (Table 1 and SI Scheme 1) were used as calibration standards. The accuracy of the method was verified using, a known drug molecule containing sulfur; methylthioninium chloride **3**, commercially available sulfate standard solution and three certified reference materials (CRMs): RM8415 (whole egg powder); BCR-062 (olive leaves) and seronorm (trace elements in urine blank) whose total sulfur contents are known were analysed. The detection limits for sulfur by HPLC ranged from 1.00 to  $2.03 \times 10^{-4}$  mg/mL using either compound **1** or **2** as standard, with a correlation coefficient >0.99. There was no statistically significant difference in the results using either compound **1** or **2** for quantification of sulfur in the samples. Recovery of sulfur in the three certified reference materials was  $101 \pm 8\%$  and compound **3** was  $78 \pm 2\%$  (Table 2). The sulfur content of the HPLC calibration standards (**1** and **2**) was within the calculated range ( $\pm 3\%$ ) allowing their use as standards in HPLC-ICP- MS/ESMS.

Quantification of compound **3** gave a recovery of  $75 \pm 3\%$  (Table 2) of the theoretical value which is similar to the value achieved during total sulfur determination. This indicates that there was no loss of compound **3** on the column, that the standards used for quantification and the methods used are of sufficient accuracy.

## 2.2. Naturally occurring cyclic peptides

As a proof of concept, purified natural products **4** and **5** were obtained from an Australian collection of the seasquirt *Lissoclinum patella*. These natural products were subjected to

HPLC-ICP-MS/ESMS. The observed peaks for each sample in both positive mode ESMS and ICP-MS were at the same retention time (tR) (Fig. 2). Quantification of compound **4** [777 (M + H)+] with tR of 23.2 min (Fig. 2A) revealed that the total solid mass of compound **4** in the analysed sample was between 29.0 and 30.8% (Table 3). Compound **5** [757 (M + H)+] with a tR of 24.3 min (Fig. 2B) had between 84 and 89% total solid in the analysed sample (Table 3), using the developed method for quantification with compounds **1** or **2** as standard.

### 2.3 Biosynthetic peptides

For HPLC-ICP-MS quantification, interferences were efficiently removed in the ICP- MS/MS with selection of dual  $m/z$ , for sulfur quantification, by measuring S,  $m/z$  32 and 34 were obtained as  $32S16O^+$  and  $34S16O^+$  preventing  $m/z$  48 and 50 interferences.<sup>66</sup> Cyclic peptides **6–10** were extracted from chemoenzymatic reaction mixtures using SPE and subsequently identified and quantified by HPLC-ICP-MS/ESMS. Solutions of samples **4** to **10** for species quantification were injected in triplicate and results are given as mean  $\pm$  SD except **8** and **9** (Table 3). These samples showed the presence of the respective peptides at different tRs (Figs. S1–S5 in Supporting Information) the sulfur peak areas at each tRs for each compound was used for their individual quantification. Quantification results of the samples revealed that compound **6** and **7** contained 39.5% and 3.6%, of the desired peptides respectively, while compound **8** contributed 75.8% to the analysed fraction, 5.0% of compound **9** was present in the analysed sample and compound **10** contained 11.5% of the peptide. RP-SPE method is useful for desalting and fractionation for compound before quantification, however data show that the estimated weight of samples was influenced by significant amounts of non-targeted compounds (data not shown) may be the reason for observed low concentrations for **6**, **7**, **9** and **10** after quantification, compared to the data obtained for **8**, which was purified by HPLC. Recent studies by Møller et al.<sup>67</sup> for peptides in human plasma and Hermann et al.<sup>68</sup> report for S-containing proteins shows the applicability of this method for accurate quantification of peptides.

### 2.4. Comparison of extraction methods

Quantification of samples obtained using various extraction methods for compound **10** revealed that reverse phase solid phase extraction RP-SPE gave optimum compound recovery and purity (Table 4). The protein concentrator and crude sample showed more peaks at retention times before 5 min due to high concentration of inorganic sulfate (Fig. S6). This confirms the need for SPE in sample preparation of target compounds/analytes,<sup>69,70</sup> as it increases the recovery of the compounds by removing the salts from the reaction buffer by selective isolation/fractionation of the cyclic peptides from the reaction mixture. This is consistent with work carried out by Lorocho et al. using RP- SPE for phosphopeptide fractionation.<sup>71</sup> The protein concentrator fractions also showed the presence of other non-identified sulfur containing compounds, which eluted through the filter with the compound of interest as the filter does not selectively isolate the apolar cyclic peptides from the more polar linear peptides, in contrast to the SPE process, hence reducing the percentage purity of the extract. We also observed that the 70 Å SPE cartridge with a smaller pore size had a higher sample yield for our compounds in comparison to the 125 Å SPE cartridge.

### 2.3 Biosynthesis. 2.5. Verification of quantification by NMR

Compound **11** was used as an external reference material for calculating the ERETIC concentration of cyclic peptides. Validation of this method for our system was achieved by comparing the calculated ERETIC concentration to that obtained by UV-absorbance at 280 nm. A 500  $\mu$ L DMSO- $d_6$  solution of **12** gave a theoretical concentration of 13 mM, equating to 5.1 mg of **12** by UV. A qNMR spectrum of **11** was recorded and one of the benzyl-hydrogen peaks was integrated, set to 10 mM and used for the ERETIC reference. Compound **12** was diluted to 600  $\mu$ L and qNMR spectrum was recorded. The distinct indole nitrogen peak was

integrated, and its value compared to that of the ERETIC reference which gave a concentration of 13 mM, which corresponded to a total of 5.1 mg of **12** (see Fig. S7 for <sup>1</sup>H NMR spectra). The total solid amount of **12** determined via UV absorbance and ERETIC quantification were with 5.06 and 5.08 mg respectively similar, thus showing that qNMR can be used to accurately determine the total solid in a purified cyclic peptide.

## 2.6. Peptide quantification by NMR

Quantification of the naturally occurring peptides **4** and **5** (Table 5 and Figs. S8 and S10) showed that compound **4** was 99% pure and compound **5** was 75% pure. The synthetic peptides subsequently quantified (Table 5 and Figs. S11–S14) showed that compound **13** contained of 21% of analysed sample, compound **14** contained 34% of the peptide while **15** and **16** contained 19% and 33% of the total solid of the analysed samples respectively. Given the high purity of compounds **13–16** we suggest that the low percentage of compound per total mass of powder can be attributed to significant retention of water during the freeze-drying process, which is supported by a large water peak (~3.3 ppm) in the NMR spectra (Figs. S11–14) similar to the finding of Frank et al.<sup>72</sup> analytical data presented shows that the actual quantity compounds were under estimated in the preparation of the stock solution.

## 3 Conclusions

The samples batch containing **4** and **5** for the respective ICP-MS and qNMR quantification were different. A low compound recovery for **4** in the ICP-MS quantification compared to the qNMR method was attributed to the presence of other unidentified compound(s) which added to the weight of the purified compound used for analysis; assuming that ionization efficiency was equal, on calculation of the extracted ion peak area with the  $m/z$  for **4** used for each quantification method, the ICP-MS sample had only 48% while the NMR sample had 87% of the compound mass. This may be the reason for the difference in quantification observed.

Accurate quantification of natural and non-natural modified cyclic peptides at various stages of purification by HPLC-ICP-MS/ESMS and <sup>1</sup>H qNMR spectroscopic without the use of authentic standards is possible using these methods. Whereas the ICP-MS method would be suitable for very small sample sizes with low purity and compounds containing a target element, the NMR method requires larger sample size and higher purity. Our data shows that these quantification methods can be applied to new compounds without authentic standards as they are not species specific but rely on elemental constitution of each compound. Application of these methods is possible for non-cyclic peptides as we were able to identify other organic and inorganic sulfur species using HPLC-ICP-MS/ESMS. These methods also eliminate the drawbacks associated with quantification by only HPLC, UV or ESMS and polyatomic spectral interference associated with ICP-MS sulfur quantification. Data obtained also show that sulfur quantification can be used to measure the purity of peptides and product yield using different extraction methods accurately from microgram to milligram quantity. ERETIC based proton qNMR can be used to quantify peptides in the presence or absence of heteroatoms.

## 4. Experimental

### 4.1. Materials/methods

#### 4.1.1. Sample

Samples used for this work, listed in Table 1 include azole containing cyclic peptides isolated from *Lissoclinum patella* sourced from Davies Reef (the Great Barrier Reef), Australia, from a collection made in 2006, and analogues synthesised using recombinant biosynthetic enzymes using the method previously reported in Houssen et al.<sup>61</sup>

#### 4.1.2. Reagents and chemicals

Milli-Q water (18 MΩcm, Millipore, Germany) was used throughout the experiments. HPLC-solvents of highest purity available (methanol, acetonitrile and trifluoroacetic acid) were obtained from Sigma Aldrich (UK), whereas formic acid (>95% reagent grade) was obtained from Fluka, UK. Nitric acid (69%, p.a.) and hydrogen peroxide (30%, trace select) were obtained from Fisher (UK) and DMSO-*d*<sub>6</sub> (99.8% purity manufactured by Cambridge Isotope Laboratories, USA). Cysteine **1** and *N*-Acetylcysteine **2** used as sulfur standards were obtained from Sigma (UK) and anthranilic acid **11** used as ERETIC standard was >99.5% purity from Sigma-Aldrich, UK. Sulfur standard (1 g/L) for total sulfur determination, rhodium and gallium (1 g/L) were obtained from High-Purity Standards (USA). Certified reference materials for total sulfur determination were RM8415 (Whole egg powder, NIST, USA), BCR-062 (olive leaves, IRMM Geel) and Seronorm Trace elements in urine blank (Sero, Norway) and the in-house material methylthioninium chloride **3**.

#### 4.1.3. Standards for ICP-MS

Standards for total sulfur determination were prepared in 2% (v/v) nitric acid. Sulfur standards **1** and **2** for HPLC were prepared freshly each day by dissolution in water with a concentration range between 5 and 100 mg S/kg.

#### 4.1.4. Microwave digestion for total S

For total sulfur determination in RM8415 and BCR-062 both materials were digested using an open microwave system (MARS5, CEM, USA) with 2 mL nitric acid and 1 mL hydrogen peroxide for 30 min at 95 °C. After cooling the samples were diluted with water to 2% (v/v) nitric acid. Seronorm urine and compound **3** (dissolved in water) were diluted using 2% (v/v) nitric acid before measurement. The HPLC standards were also acidified with nitric acid (final concentration 2% v/v) for verification of sulfur concentration.

#### 4.1.5. Solid phase extraction (SPE)

Two types of SPE cartridges with silica as the sorbent were used to extract the peptides from protein mixtures using a vacuum extraction manifold (Phenomenex Strata 1 g C8, 55 µm 70 Å and Waters Sep – Pak 1 g C8, 37–55 µm 125 Å). Each cartridge was conditioned with 5 column volumes (CV) of methanol and 5 CV of water after which the sample was loaded, washed with equal volume of water and subsequently eluted with 10 CV of 50: 50 v/v water: methanol, 10 CV of 100% methanol, 10 CV of 100% acetonitrile and finally with 10 CV of 0.05% trifluoroacetic acid in acetonitrile. The methanol and acetonitrile fractions were combined and concentrated under a stream of nitrogen. Residual dry sample was then weighed and reconstituted with methanol before use. Phenomenex Strata cartridges were used for extractions for all the samples studied while Waters Sep – Pak was used only for comparison of extraction method for compound **10**.

#### 4.1.6. Extraction methods

An aliquot of compound **10** enzymatic reaction mixture was divided into 12 vials containing 3.2 mL each, to allow triplicate measurements of each sample treatment method. The first set of three sample aliquots were extracted using Phenomenex strata 1 g; 70 Å C8 SPE, the methanol and acetonitrile eluates were then combined, concentrated, weighed and reconstituted in methanol for analysis, using the same treatment, the next set of samples was extracted using Waters 1 g; 125 Å C8 SPE column. The third set sample aliquots were transferred into 30 mL protein filters (protein concentrator MWCO 10,000 from GE Healthcare) and centrifuged at 2000 revolutions per minute (rpm) at 4 °C for 40 min, the resulting filtrate was transferred into pre-weighed glass vials and the supernatants were transferred into 2 mL protein filters, and centrifuged for 30 min at 2000 rpm the resulting filtrate was transferred into the initial filtrate, frozen and then freeze dried before re-weighing. The samples were then dissolved in Milli-Q water for analysis, the supernatants obtained after filtration using the 2 mL protein filter was transferred into a separate pre-weighed glass vials, frozen and then freeze dried before reweighing. This was then reconstituted in Milli-Q water. The last set of 3.2 mL sample aliquot

crude sample was put in pre-weighed vials, frozen and freeze dried; sample weight was obtained before dissolving in Milli-Q water for analysis.

#### 4.1.7. <sup>1</sup>H NMR quantification

Pure (95%) **12** (5.6 mg) of was dissolved in 500 µL DMSO-*d*<sub>6</sub>. The concentration of **12** in solution was determined first by A280 using a theoretical extinction coefficient of 5500 M<sup>-1</sup> cm<sup>-1</sup> as calculated by *ExpASy ProtParam*. A280 measurements were performed on a NanoDrop ND-1000 spectrophotometer, which returned a concentration of 13 mM, equating to 5.1 mg of product. The solution was diluted to 600 µL and transferred to an NMR tube for qNMR and the spectrum recorded. A 1 M solution of **11** was prepared in DMSO and subsequently diluted to 10 mM using DMSO-*d*<sub>6</sub> before obtaining the qNMR spectrum. From this spectrum one of the well-defined and isolated benzyl-hydrogen peaks was integrated and set to 10 mM as an ERETIC reference. The concentration of **12** was calculated by integrating the well-defined and isolated indole nitrogen peak and comparing the value with that of the ERETIC reference. Synthetic peptides **13–16** were quantified using the same procedure, data were analysed using *TopSpin* software (Bruker).

The dry mass of **4** and **5** weighed and dissolved in 800 µL of DMSO-*d*<sub>6</sub>, 99 mM stock solution of **11** in DMSO-*d*<sub>6</sub> was prepared from which 50 mM and 20 mM were made up. Proton NMR was acquired for the standards and samples sequentially on the same day using 5 mm tubes. Data was analysed using qNMR on MestReNova software for compound quantification.

#### 4.2. Instrumentation/methods

##### 4.2.1. ICP-MS (total sulfur determination)

An Agilent 8800 (Agilent Technologies, USA) was used for total sulfur determination. The instrument was used in MS/MS-mode using oxygen as reaction gas. The general instrument parameters were optimized for robust plasma conditions using Ni-cones. Sulfur was measured in mass-shift mode on *m/z* 48 (32S- $\rightarrow$  32S16O) and *m/z* 50 (34S - $\rightarrow$  34S16O). Gallium (10 µg/kg) was used as internal standard.

##### 4.2.2. Preparative HPLC separation

Reverse phase liquid chromatographic separation was used for sample separation using an Agilent 1260 infinity HPLC system; each sample separation gradient was developed depending on the best separation chromatogram observed using a UV detector. Chromatographic methods are as shown in Table 6, methods A and B were used for the purification of *Lissoclinum patella* extract to obtain **4** and **5**, while methods C and D were analytical methods used for HPLC-ICP-MS/ESMS.

##### 4.2.3. HPLC- ICP-MS/ESMS

An Agilent 1100 HPLC system consisting of cooled autosampler, quaternary pump and column thermostat was used for the separation of the samples. The autosampler was cooled to 4 °C, whereas the column was held at 35 °C. A sample volume of 20 µL was used throughout. The columns and separation conditions used are summarized in Table 6 methods C and D. The column effluent was split 1:4 using a QuickSplit Post-Column Flow splitter (ASI, USA), with 1 part of the effluent infused into the ICP-MS and 3 parts into the ESMS.

The ICP-MS used was an 8800 Agilent system (Agilent Technologies, USA). The instrument was used in organic mode including Pt-cones, small ID torch and PFA- micronebulizer. Further instrument parameters are given in Table 7; the instrument was optimized daily for highest sensitivity under robust plasma conditions. Sulfur was determined using oxygen in the reaction cell in MS/MS mode using the mass-shifts of *m/z* 48 (32S- $\rightarrow$  32S16O) and *m/z* 50 (34S34- $\rightarrow$  34S16O). Rhodium (10 µg/L) in 1% nitric acid was used as continuous internal standard. To correct for intensity shifts due to the methanol gradient a blank run using a continuous internal standard containing sulfur and rhodium as described in Amayo et al.<sup>65</sup> was used for correction.

An LTQ-Orbitrap Discovery from Thermo Scientific, UK was the ESMS system used for molecular identification. The splitter outlet (3 parts) was directly connected to the ES-inlet. The instrument was optimized daily for highest sensitivity and mass accuracy in positive mode. Further instrument parameters can be found in Table 7.

#### 4.2.4. NMR

NMR experiments were performed at 25 °C for **4** and **5** in a Bruker Ascend 400 MHz NMR machine with a Z116098\_0444 (PA BBO 400S1 BBF-H-D-05 Z SP) probe while Bruker DRX500 spectrometer equipped with a 5 mm TXIz probe was used for **13–16**. Data acquisition for all compounds was done at 64 scans, 10.00 compensate, 90° pulse and 30 s Delay.

#### Acknowledgments

MJ, JHN, WEH, LT gratefully acknowledge support from the the Leverhulme Trust (RPG 2012-504). JT and AR were funded by EU-FP7 project ‘PharmaSea’ (contract 312184) and ARM and GM were funded by Scottish Enterprise High Growth Spinout ProgrammePS7305CA38.

#### Legends

Fig. 1. Structures of some modified cyclic peptides in the cyanobactin family showing heterocycles, epimerized stereocentres and prenylated residues in trunkamide A.

Fig. 2. Separation of compound **4** and **5** containing solids and detection by ICP-MS (red) and ESMS (blue), A) ICP-MS and extracted ion count (EIC) chromatograms of compound **4**, B) ICP-MS and extracted ion count (EIC) chromatograms of compound **5**.

#### Tables

Table 1. Names of compounds studied with their molecular formula and molecular masses in g/mol.

Table 2. Sulfur quantification results for the concentration of compound **3** and certified reference materials in mg compound/g solution.

Table 3. Theoretical concentration of samples, average amount of compounds recovered after quantification by sulfur for compounds **4**, **5**, **6**, **7**, **8**, **9** and **10** in µg/m, % compound recovery and purification methods.

Table 4. Sample total dry weight, percentage purity and yield for each extraction method applied to compound **10** based on enrichment factor.


Table 5. Weighed mass sample, concentration of compound and % compound obtained after qNMR quantification with their respective unit.

Table 6. LC separation gradient for the purification of compound **7** and **8** (method A and B) and methods C and D used for quantification.


Table 7. Instrumentation parameter for ICPMS and ESMS optimized for peptide quantification.



1



2



Name/Sequence	Molecular formula	Mass (g/mol)
Cysteine (1)	C <sub>3</sub> H <sub>7</sub> NO <sub>2</sub> S	121.16
N-acetyl cysteine (2)	C <sub>5</sub> H <sub>9</sub> NO <sub>3</sub> S	163.19
Methylthioninium chloride (3)	C <sub>16</sub> H <sub>18</sub> ClN <sub>3</sub> S	319.85
Patellamide D (4)	C <sub>38</sub> H <sub>48</sub> N <sub>8</sub> O <sub>6</sub> S <sub>2</sub>	776.97
Ascidiacyamide (5)	C <sub>36</sub> H <sub>52</sub> N <sub>8</sub> O <sub>6</sub> S <sub>2</sub>	756.98
Cyclo[IFTV(ThH)I(ThH)V(ThH)] (6) <sup>a</sup>	C <sub>44</sub> H <sub>65</sub> N <sub>9</sub> O <sub>7</sub> S <sub>3</sub>	928.24
Cyclo[ITM(ThH)ITM(ThH)] (7) <sup>a</sup>	C <sub>36</sub> H <sub>60</sub> N <sub>8</sub> O <sub>8</sub> S <sub>4</sub>	861.17
Cyclo[I(MeOxH)V(ThH)I(MeOxH)V(ThH)] (8) <sup>b</sup>	C <sub>36</sub> H <sub>56</sub> N <sub>8</sub> O <sub>6</sub> S <sub>2</sub>	761.01
Cyclo[ITA(ThH)ITF(ThH)] (9) <sup>a</sup>	C <sub>38</sub> H <sub>56</sub> N <sub>8</sub> O <sub>8</sub> S <sub>2</sub>	817.03
Cyclo[GITA(ThH)I(ThH)V(ThH)] (10) <sup>a</sup>	C <sub>36</sub> H <sub>56</sub> N <sub>8</sub> O <sub>7</sub> S <sub>3</sub>	809.07
Anthranilic acid (11)	C <sub>7</sub> H <sub>7</sub> NO <sub>2</sub>	137.14
Cyclo[VGAGIGWP] (12) <sup>c</sup>	C <sub>36</sub> H <sub>51</sub> N <sub>9</sub> O <sub>8</sub>	737.86
Cyclo[I(MeOxH)A(Thz)I(MeOxH)A(Thz)] (13) <sup>d</sup>	C <sub>32</sub> H <sub>44</sub> N <sub>8</sub> O <sub>6</sub> S <sub>2</sub>	700.87
Cyclo[IPA(Thz)I(MeOxH)F(Thz)] (14) <sup>d</sup>	C <sub>39</sub> H <sub>50</sub> N <sub>8</sub> O <sub>6</sub> S <sub>2</sub>	790.32
Cyclo[IPA(Thz)IPFThz] (15) <sup>e</sup>	C <sub>40</sub> H <sub>52</sub> N <sub>8</sub> O <sub>6</sub> S <sub>2</sub>	805.02
Cyclo[ITA(Thz)IPF(Thz)] (16) <sup>e</sup>	C <sub>39</sub> H <sub>52</sub> N <sub>8</sub> O <sub>7</sub> S <sub>2</sub>	809.01

Modified cyclic peptides prepared from the corresponding linear peptides by processing with:  
A TruD heterocyclase, which converts Cys to thiazoline, followed by PatG<sub>mac</sub>.

B PatD heterocyclase, which converts Cys, Ser, Thr to thiazoline, oxazoline and methyl oxazoline respectively, followed by PatG<sub>mac</sub>.

C Macrocyclization by PatG<sub>mac</sub>.

D MicD heterocyclase, which converts Cys to thiazoline, Thr to methyl oxazoline, followed by PatG<sub>mac</sub>, followed ArtGox.

E LynD heterocyclase, which converts Cys to thiazoline, followed by PatG<sub>mac</sub> and ArtGox.

2

<b>Sample (n = 3)</b>	<b>Theoretical mg compound/g</b>	<b>Found mg compound/g</b>
<b>3</b>	1.41	$1.34 \pm 0.0439$
<b>Total S in CRM's</b>	<b>Certified Value</b>	<b>mg/kg</b>
RM8451	$5120 \pm 500$	$4762 \pm 54$
BCR-062	1600 (indicative value)	$1588 \pm 32$
Seronorm urine	545 (513–577)	$617 \pm 123$

3

<b>Sample</b>	<b>Theoretical concentration (<math>\mu\text{g}</math> compound/mL)</b>	<b>Average compound recovery <math>\mu\text{g}</math> compound/mL</b>	<b>% Compound recovery</b>	<b>Purification method</b>
<b>4a</b>	97.80	$28.40 \pm 0.725$	29.70	HPLC
<b>4b</b>	49.41	$15.22 \pm 0.465$	30.80	HPLC
<b>5a</b>	135.6	$115.0 \pm 1.991$	84.80	HPLC
<b>5b</b>	41.70	$37.13 \pm 1.112$	89.00	HPLC
<b>6</b>	899.4	$355.0 \pm 3.098$	39.50	SPE
<b>7</b>	1400	$50.33 \pm 4.752$	3.60	SPE
<b>8</b>	250.0	189.4	75.80	HPLC
<b>9</b>	987.5	49.78	5.00	SPE
<b>10</b>	1228	$141.6 \pm 17.36$	11.50	SPE

a and b are different concentrations for each sample.

4

<b>Sample</b>	<b>Sample total dry weight (mg)</b>	<b>Ratio of compound/total solid</b>	<b>% Purity</b>	<b>% Compound recovery</b>
Crude	0.30	0.13	$0.046 \pm 0.0072$	
SPE_125 Å	0.031	0.082	$8.5 \pm 2.5$	10
SPE_70 Å	0.059	0.099	$14 \pm 3.2$	19
Supernatant	0.054	0.12	$1.8 \pm 0.21$	18
Filtrate	0.18	0.18	$0.28 \pm 0.15$	61

5

<b>Sample</b>	<b>Weighed mass of sample (mg)</b>	<b>Experimental mass of compound (mg)</b>	<b>% Compound recovery</b>
<b>4</b>	5.70	5.67	99
<b>5</b>	8.10	6.05	75
<b>13</b>	1.50	0.31	21
<b>14</b>	4.97	1.69	34
<b>15</b>	1.60	0.30	19
<b>16</b>	5.40	0.54	33

6

<b>Instrument parameter</b>	<b>Method A preparative</b>	<b>Method B preparative</b>	<b>Method C analytical</b>	<b>Method D analytical</b>
Column	Sunfire C18 10 $\mu$ m 10 $\times$ 250 mm D	YMC-Pack pro C4, 3 $\mu$ m 12 nm, 150 $\times$ 4.6 mm D	Agilent XBD-Eclipse C18, 4.6 $\times$ 150 mm D Poresize 5 $\mu$ m	YMC-Pack Pro C4 150 $\times$ 4.6 mmD, S-3 $\mu$ m
Flowrate	1.5 mL/min	1.0 mL/min	0.9 mL/min	0.9 mL/min
Injection volume	200 $\mu$ L	100 $\mu$ L	20 $\mu$ L	20 $\mu$ L
Column temperature	30 $^{\circ}$ C	30 $^{\circ}$ C	35 $^{\circ}$ C	35 $^{\circ}$ C
Solvent A	milliQ water	milliQ water	0.1% (v/v) Formic acid in water	0.1% (v/v) Formic acid in water
Solvent B	Acetonitrile	Acetonitrile	0.1% (v/v) Formic acid in Methanol	0.1% (v/v) Formic acid in Methanol
Gradient	0–20 min: 0–100% B 20–32 min 100% B	0–25 min: 0–100% B 20–32 min 100% B	0–25 min: 0–100% B 25–35 min 100% B	0–20 min: 10–100% B 20–25 min 100% B

<b>Instruments parameter</b>	<b>Value</b>
ICP-MS	Agilent 8800
Mode	Organic (Pt- cones, organic torch, PFA- micronebulizer)
HF	1600 W
Nebulizer- type	Microflow
Nebulizer gas	0.91 L/min
Optional gas	6% oxygen (80:20 Ar:O <sub>2</sub> )
Plasma gas	0.98 Lmin
Coolant gas	15.5 L/min
Reaction cell gas	O <sub>2</sub>
Reaction cell gas flow	0.3 mL/min
ESMS:	LTQ Orbitrap Discovery (Thermo Scientific)
Mode	Positive
Resolution	30,000
MSMS mode	automatic
Ionspray voltage	4.5 KV

## References

- 1 D.R. Barnidge, E.A. Dratz, T. Martin, L.E. Bonilla, L.B. Moran *Anal Chem* (2003), pp. 445-451
- 2 L. Zhu, C. Tamvakopoulos, D. Xie, et al. *J Biol Chem*, 278 (2003), pp. 22418-22423
- 3 W. Weckwerth, L. Willmitzer, O. Fiehn *Rapid Commun Mass Spectrom* (2000), pp. 1677-1681
- 4 H. John, M. Walden, S. Schafer, S. Genz, W. Forssmann *Anal Bioanal Chem* (2004), pp. 883-897
- 5 Goltzman, D. *Nat Rev Drug Discov*, 1, 784–796.
- 6 S.A. Douglas *Curr Opin Pharmacol* (2003), pp. 159-167 Article PDF (168KB)
- 7 C.A.J. Hajee, H.A. van Rhijn, J.J.P. Lasaroms, H.J. Keukens, J. de Jong *Analyst*, 126 (2001), pp. 1332-1338
- 8 D.S. Stegehuis, U.R. Tjaden, C.M.B. van den Beld, J. van der Greef *J Chromatogr*, 549 (1991), pp. 185-193
- 9 G.F. Pauli, T. Gödecke, B.U. Jaki, D.C. Lankin *J Nat Prod* (2012), pp. 834-851
- 10 M.J. Peffers, R.J. Beynon, P.D. Clegg *Int J Mol Sci* (2013), pp. 20658-20677
- 11 A. Prange, D. Pröfrock  
*J Anal At Spectrom*, 23 (2008), pp. 432-459
- 12 S.A. Gerber, J. Rush, O. Stemman, M.W. Kirschner, S.P. Gygi *Proc Natl Acad Sci U. S. A*, 100 (2003), pp. 6940-6945
- 13 E.C. Yi, X.J. Li, K. Cooke, et al. *Proteomics*, 5 (2005), pp. 380-385
- 14 K.C. Hansen, G. Schmitt-Ulms, R.J. Chalkley, J. Hirsch, M.A. Baldwin, A.L. Burlingame  
*Mol Cell Proteomics*, 2 (2003), pp. 299-314
- 15 J. Qu, R.M. Straubinger  
*Rapid Commun Mass Spectrom*, 19 (2005), pp. 2857-2864
- 16 A. Rainczuk, M. Condina, M. Pelzing, et al. *J Proteome Res*, 12 (2013), pp. 4074-4088
- 17 A. Schmidt, J. Kellermann, F. Lottspeich *Proteomics*, 5 (2005), pp. 4-15
- 18 F. Lottspeich, J. Kellermann  
*Methods Mol Biol*, 753 (2011), pp. 55-64
- 19 Y. Oda, K. Huang, F.R. Cross, D. Cowburn, B.T. Chait *Proc Natl Acad Sci U. S. A*, 96 (1999), pp. 6591-6596
- 20 B. Blagoev, I. Kratchmarova, S.E. Ong, M. Nielsen, L.J. Foster, M. Mann *Nat Biotechnol*, 21 (2003), pp. 315-318
- 21 M. Krüger, M. Moser, S. Ussar, et al. *Cell*, 134 (2008), pp. 353-364
- 22 L. Dayon, A. Hainard, V. Licker, et al. *Anal Chem*, 80 (2008), pp. 2921-2931
- 23 L. Ting, R. Rad, S.P. Gygi, W. Haas *Nat Methods*, 8 (2011), pp. 937-940
- 24 A.N. Kettenbach, J. Rush, S.A. Gerber *Nat Protoc*, 6 (2011), pp. 175-186
- 25 A. Prakash, D.M. Tomazela, B. Frewen, et al. *J Proteome Res*, 8 (2009), pp. 2733-2739
- 26 Y. He, Y. Zhang, C. Wei, C. Li, Y. Gao, R. Liu *Appl Spec Rev*, 49 (2014), pp. 492-512
- 27 C. Osama, C. Diego, M. John *J Pharm Biomed Anal*, 113 (2015), pp. 2-20
- 28 R. Ahrends, S. Pieper, A. Kuhn, et al. *Mol Cell Proteomics*, 6 (2007), pp. 1907-1916
- 29 A. Pereira-Navaza, J. Ruiz-Encinar, A. Sanz-Medel *Angew Chem Int Ed*, 46 (2007), pp. 569-571
- 30 M. Xu, L.M. Yang, Q.Q. Wang *J Anal At Spectrom*, 23 (2008), pp. 1545-1549
- 31 M. Xu, X.W. Yan, Q.Q. Xie, L.M. Yang, Q.Q. Wang *Anal Chem*, 82 (2010), pp. 1616-1620
- 32 S. Theiner, C. Kornauth, H.P. Varbanov, et al. *Metallomics*, 7 (2015), pp. 1256-1264
- 33 M. Wind, A. Wegener, A. Eisenmenger, R. Kellner, W.D. Lehmann *Angew Chem Int Ed*, 42 (2003), pp. 3425-3427
- 34 X.W. Yan, L.M. Yang, Q.Q. Wang *Angew Chem Int Ed*, 50 (2011), pp. 5130-5133
- 35 X.W. Yan, Y.C. Luo, Z.B. Zhang, et al. *Angew Chem Int Ed*, 51 (2012), pp. 3358-3363

- 36 S. El Balkhi, J. Poupon, J.M. Trocello, F. Massicot, F. Woimant, O. Laprévotte *Anal Chem*, 82 (2010), pp. 6904-6910
- 37 Y. Suzuki, A. Nobusawa, N. Furuta *Anal Sci*, 30 (2014), pp. 551-559
- 38 K. Bierla, J. Bianga, L. Ouerdane, J. Szpunar, A. Yiannikouris, R. Lobinski *J Proteomics*, 87 (2013), pp. 26-39
- 39 M. Wang, W. Feng, W. Lu, et al. *Anal Chem*, 79 (2007), pp. 9128-9134
- 40 M.A. Bernstein, S. Sýkora, C. Peng, A. Barba, C. Cobas *Anal Chem*, 85 (2013), pp. 5778-5786
- 41 M.J. Albers, T.N. Butler, I. Rahwa, et al. *Magn Reson Med*, 61 (2009), pp. 525-532
- 42 G.A. Barding Jr., R. Salditos, C.K. Larive *Anal Bioanal Chem*, 404 (2012), pp. 1165-1179
- 43 S. Akoka, L. Barantin, M. Trierweiler *Anal Chem*, 71 (1999), pp. 2554-2557
- 44 S. Lane, B. Boughtflower, I. Mutton, et al. *Anal Chem*, 77 (2005), pp. 4354-4365
- 45 F. Giordanetto, J. Kihlberg *J Med Chem* (2014), pp. 278-295
- 46 P.G. Arnison, M.J. Bibb, G. Bierbaum, et al. *Nat Prod Rep* (2013), pp. 108-160
- 47 W.E. Houssen, M. Jaspars *ChemBioChem*, 11 (2010), pp. 1803-1815
- 48 Y. Goto, Y. Ito, Y. Kato, S. Tsunoda, H. Suga *Chem Biol* (2014) 788-774
- 49 E.M. Drigger, S.P. Hale, J. Lee, N.K. Terrett *Nat Rev Drug Discov* (2008), pp. 608-624
- 50 D.B. Longley, P.G. Johnston *J Pathol* (2005), pp. 275-292
- 51 B.A. Williams, J. R. S *Cancer Lett*, 71 (1993), pp. 97-102
- 52 S.G. Aller, J. Yu, A. Ward, Y. Weng, et al. *Science*, 323 (2009), pp. 1718-1721
- 53 P.F. Long, W.C. Dunlap, C.N. Battershill, M. Jaspars *ChemBioChem*, 6 (2005), pp. 1760-1765
- 54 E.W. Schmidt, J.T. Nelson, D.A. Rasko, et al. *Proc Natl Acad Sci U. S. A*, 102 (2005), pp. 7315-7320
- 55 W.E. Houssen, S.H. Wright, A.P. Kalverda, G.S. Thompson, S.M. Kelly, M. Jaspars *ChemBioChem*, 11 (2010), pp. 1867-1873
- 56 J. Koehnke, A.F. Bent, D. Zollman, et al. *Angew Chem Int Ed*, 52 (2013), pp. 13991-13996
- 57 J. Koehnke, A.F. Bent, W.E. Houssen, et al. *Nat Struct Mol Biol*, 19 (2012), pp. 767-772
- 58 N. Leikoski, L. Liu, J. Jokela, et al. *Chem Biol* (2013), pp. 1033-1043
- 59 M.S. Donia, B.J. Hathaway, S. Sudek, et al. *Nat Chem Biol*, 2 (2006), pp. 729-735
- 60 A.F. Bent, J. Koehnke, W.E. Houssen, M.C.M. Smith, M. Jaspars, J.H. Naismith *Acta Cryst*, F69 (2013), pp. 618-623
- 61 W.E. Houssen, A.F. Bent, A.R. McEwan, et al. *Angew Chem Int Ed* (2014), pp. 1-5
- 62 M.D. Tianero, M.S. Donia, T.S. Young, P.G. Schultz, E.W. Schmidt *J Am Chem Soc*, 134 (2012), pp. 418-425
- 63 J.A. McIntosh, M.S. Donia, E.W. Schmidt *J Am Chem Soc*, 132 (2010), pp. 4089-4091
- 64 J.A. McIntosh, E.W. Schmidt *ChemBioChem*, 11 (2010), pp. 1413-1421
- 65 K.O. Amayo, A. Petursdottir, C. Newcombe, et al. *Anal Chem*, 83 (2011), pp. 3589-3595
- 66 J.G. Martínez-Sierra, O. Galilea San Blas, J.M. Marchante Gayón, J.I. García Alonso *Spectrochim Acta*, 108 (2015), pp. 35-52
- 67 L.H. Møller, A. Macharius, T.H. Hansen, et al. *Anal At Spectrom*, 31 (2016), p. 1877
- 68 G. Hermann, L.H. Moller, B. Gammelgaard, J. Hohlweg, D. Mattanovich, S. Hann, et al. *J Anal At Spectrom*, 31 (2016), pp. 1830-1835
- 69 B. Buszewski, M. Szultka  
*Crit Rev Anal Chem*, 42 (2012), pp. 198-213
- 70 M. Rogeberg, H. Malerød, H. Hanne Roberg-Larsen, C. Aass, S.R. Wilson *J Pharm Biomed Anal*, 87 (2014), pp. 120-129
- Article PDF (2MB)
- 71 S. Loroch, R.P. Zahedi, A. Sickmann *Anal Chem*, 87 (2015), pp. 1596-1604

72 O. Frank, J.K. Kreissl, A. Daschner, T. Hofmann J Agric Food Chem, 62 (2014), pp. 2506-2515